Khurram Jamil Sells 7,557 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 7,557 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $3.14, for a total transaction of $23,728.98. Following the completion of the transaction, the insider owned 7,557 shares in the company, valued at approximately $23,728.98. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Khurram Jamil also recently made the following trade(s):

• On Tuesday, May 26th, Khurram Jamil sold 568 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.10, for a total transaction of $1,760.80.

Galectin Therapeutics Stock Up 17.5%

Shares of GALT stock opened at $4.97 on Friday. Galectin Therapeutics Inc. has a 12-month low of $2.03 and a 12-month high of $7.13. The company has a market capitalization of $327.32 million, a PE ratio of -12.12 and a beta of 0.47. The firm has a 50 day moving average price of $2.55 and a two-hundred day moving average price of $3.09.

Galectin Therapeutics (NASDAQ:GALT) last announced its earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). As a group, research analysts expect that Galectin Therapeutics Inc. will post -0.37 EPS for the current year.

Institutional Trading of Galectin Therapeutics

Large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its stake in Galectin Therapeutics by 1,197.3% in the fourth quarter. Royal Bank of Canada now owns 6,175 shares of the company’s stock valued at $25,000 after acquiring an additional 5,699 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of Galectin Therapeutics in the 4th quarter valued at $43,000. Bank of America Corp DE boosted its holdings in shares of Galectin Therapeutics by 101.4% in the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after purchasing an additional 19,316 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Galectin Therapeutics in the 4th quarter valued at $59,000. Finally, Hudson Bay Capital Management LP bought a new position in shares of Galectin Therapeutics in the 3rd quarter valued at $63,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Analyst Ratings Changes

GALT has been the topic of several recent research reports. Weiss Ratings upgraded Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research report on Tuesday. Finally, Wall Street Zen raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.